Vertex and lonza to build dedicated manufacturing facility for type 1 diabetes (t1d) cell therapies

Boston & basel, switzerland--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) and lonza (six: lonn) today announced a strategic collaboration to support the manufacture of vertex's portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with t1d, currently focusing on the vx-880 and vx-264 programs that are currently in clinical trials. vertex's first clinical program, vx-880, has already demonstrated clinical pro.
VRTX Ratings Summary
VRTX Quant Ranking